Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Relapsed/Refractory ENKTL and EBV-DLBCL
NCT03586024Phase 2Withdrawn
- Sponsor
- Abramson Cancer Center
- Start
- Mar 2019
- Primary completion
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in Extranodal NK/T-cell lymphoma (ENKTL) and diffuse large B-cell lymphoma (DLBCL) (2 cohorts), sponsored by Abramson Cancer Center. Primary endpoint: Number of adverse events at 36 months. Planned start Mar 2019; status: withdrawn.
02
Drugs
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03586024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586024.